Seven Southern states account for 70% of US orders for monoclonal antibodies, the treatment of choice for many vaccine refusers
- Orders for doses of
monoclonal antibodiesjumped from 27,000 in July to 168,000 doses per week in late August.
- Kentucky Gov. Andy Beshear said Thursday that the state is running low on the
- Monoclonal antibody treatment for
COVID-19received FDA authorization in 2020.
70% of orders placed for doses of monoclonal antibodies came from seven
As orders jumped from 27,000 in July to 168,000 doses per week in late August, the Biden administration told states to prepare for the nation's dwindling supply of the treatment and expect scaled-back shipments as a result of increasing demand from less-vaccinated Southern states, the Times reported.
Several states, including Missouri, Texas, and Florida, have expanded access to monoclonal antibody treatment in recent weeks, despite each of their governors opposing
"We're going to be at a point, within a week, where there are going to be folks that want and probably need this treatment and we're not going to have enough of it," Kentucky Gov. Andy Beshear said Thursday, according to WLWT.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful antigens such as viruses, according to the Food and Drug Administration (FDA). The treatment, which is no less experimental than COVID-19 vaccines, received FDA authorization in 2020.
- Reliance Industries net profit more than triples in the last eight quarters to $2.8 billion
- Reliance Retail earns $1.3 billion more than its best-ever quarter
- Reliance Jio is making the most money it has ever made from its subscribers
- Twitter’s long-awaited hexagonal profile pictures that give bragging rights to NFT HOLDers is here — but not everyone loves it
- IIT-Bombay’s annual socio-weekend to start from January 22